Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Pharma companies at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

34 pharma companies are at ASH 2026 — 115 presentations on the program and 29 with a booth in the exhibit hall. Most represented: Bristol Myers Squibb (11 on the program), AstraZeneca (9 on the program), AbbVie (7 on the program). 31 of them have their own page in this guide. As of Nov 10, 2026.

All 1,934 organizations at ASH 2026 →

Topic
Top represented
Showing 1–2 of 34 organizations
OrganizationASH 2026 Attendance
Large pharma
Global biopharmaceutical company with hematology medicines in myeloma, lymphoma, leukemia and anemia, including CAR T-cell therapies.
Booth
Exhibiting at Booth 1313
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity.
Symposium hosted by PeerView Institute for Medical Education
Myeloma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going
Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading.
Myeloma · Cell & gene
Symposium
Fri Dec 11
11:00am–2:00pm
CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation
CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products.
Symposium hosted by Decera Clinical Education
Lymphoma · Cell & gene
Symposium
Fri Dec 11
11:00am–2:00pm
The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care
Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing.
Myeloma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going
Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies.
Leukemias
Symposium
Fri Dec 11
3:00pm–6:00pm
MDS in the Modern Era: Getting Ahead of the 8-Ball
Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access.
Leukemias
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know
Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research.
Lymphoma
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global biopharmaceutical company; hematology medicines include the BTK inhibitor acalabrutinib for CLL and mantle cell lymphoma.
Booth
Exhibiting at Booth 1339
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia
How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research.
Lymphoma
Symposium
Fri Dec 11
7:00am–10:00am
Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity.
Symposium hosted by PeerView Institute for Medical Education
Myeloma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going
Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading.
Myeloma · Cell & gene
Symposium
Fri Dec 11
11:00am–2:00pm
Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation
Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T.
Symposium hosted by PeerView Institute for Medical Education
Leukemias · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review
Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials.
Lymphoma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies
Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments.
Symposium hosted by Decera Clinical Education
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum
Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T.
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies
Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment
Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice
Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies.
Symposium hosted by National Comprehensive Cancer Network and Decera Clinical Education
Myeloma
Symposium
Fri Dec 11
3:00pm–6:00pm
Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions
How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care.
Symposium hosted by Decera Clinical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care
Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know
Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research.
Lymphoma

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from pharma companies

Tell us what you sell and we’ll find the people at these pharma companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse ASH 2026 by

Exhibit hall

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction